Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
France
/
Pharmaceuticals & Biotech
Create a narrative
Sartorius Stedim Biotech Community
ENXTPA:DIM Community
2
Narratives
written by author
0
Comments
on narratives written by author
9
Fair Values set
on narratives written by author
Create a narrative
Sartorius Stedim Biotech
Popular
Undervalued
Overvalued
Community Investing Ideas
Sartorius Stedim Biotech
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Acquisition And Efficiency Program Will Extend Human Cell Model Access
Key Takeaways Strategic acquisition of MatTek enhances innovation, potentially boosting revenue by reducing animal testing reliance and aligning with FDA shifts. Strong growth in recurring high-margin business and geographic expansion indicate sustained revenue growth and margin stabilization despite global trade tensions.
View narrative
€252.50
FV
20.3% undervalued
intrinsic discount
10.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
DIM
DIM
Sartorius Stedim Biotech
Your Fair Value
€
Current Price
€201.20
19.3% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
5b
2015
2018
2021
2024
2025
2027
2030
Revenue €4.6b
Earnings €331.5m
Advanced
Set Fair Value